New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection ...
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to ...
6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional ...
Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene ...
FORT WORTH, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
FORT WORTH, Texas, June 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results